CANCER
Outsourcing cancer immunotherapy
T cells from healthy human donors may be an important resource for outsourcing cancer immunotherapy.
E. Strønen, M. Toebes, S. Kelderman, M. M. van Buuren, W. Yang, N. van Rooij, M. Donia, M.-L. Böschen, F. Lund-Johansen, J. Olweus, T. N. Schumacher, Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337–1341 (2016). [Abstract]
M. Yadav, L. Delamarre, Outsourcing the immune response to cancer. Science 352, 1275–1276 (2016). [Abstract]
A cancer-promoting histone protein
The lysine-36–to–methionine mutation in histone H3 interferes with inhibitory chromatin marks and promotes cancer.
D. Fang, H. Gan, J.-H. Lee, J. Han, Z. Wang, S. M. Riester, L. Jin, J. Chen, H. Zhou, J. Wang, H. Zhang, N. Yang, E. W. Bradley, T. H. Ho, B. P. Rubin, J. A. Bridge, S. N. Thibodeau, T. Ordog, Y. Chen, A. J. van Wijnen, A. M. Oliveira, R.-M. Xu, J. J. Westendorf, Z. Zhang, The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science 352, 1344–1348 (2016). [Abstract]
